NASDAQ:RVLP RVL Pharmaceuticals (RVLP) Stock Forecast, Price & News $0.08 0.00 (-2.35%) (As of 02:01 PM ET) Add Compare Share Share Today's Range$0.08▼$0.0950-Day Range$0.09▼$0.5052-Week Range$0.08▼$2.42Volume16.26 million shsAverage Volume1.27 million shsMarket Capitalization$9.25 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media RVL Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside3,117.5% Upside$2.50 Price TargetShort InterestHealthy3.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.24Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.46) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector634th out of 963 stocksPharmaceutical Preparations Industry285th out of 451 stocks 3.3 Analyst's Opinion Consensus RatingRVL Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.50, RVL Pharmaceuticals has a forecasted upside of 3,117.5% from its current price of $0.08.Amount of Analyst CoverageRVL Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.21% of the float of RVL Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRVL Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RVL Pharmaceuticals has recently increased by 91.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRVL Pharmaceuticals does not currently pay a dividend.Dividend GrowthRVL Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RVLP. Previous Next 3.5 News and Social Media Coverage News SentimentRVL Pharmaceuticals has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for RVL Pharmaceuticals this week, compared to 1 article on an average week.Search Interest55 people have searched for RVLP on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added RVL Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RVL Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of RVL Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 24.20% of the stock of RVL Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for RVL Pharmaceuticals are expected to grow in the coming year, from ($0.46) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RVL Pharmaceuticals is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RVL Pharmaceuticals is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRVL Pharmaceuticals has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About RVL Pharmaceuticals (NASDAQ:RVLP) StockRVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.Read More RVLP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVLP Stock News HeadlinesSeptember 17, 2023 | americanbankingnews.comHead to Head Review: RVL Pharmaceuticals (NASDAQ:RVLP) & Qualigen Therapeutics (NASDAQ:QLGN)August 23, 2023 | finance.yahoo.comUnmasking the Value Trap: A Deep Dive into RVL Pharmaceuticals PLCSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 23, 2023 | finance.yahoo.comRVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 21, 2023 | markets.businessinsider.comRVL Pharmaceuticals (RVLP) Gets a Buy from H.C. WainwrightAugust 16, 2023 | benzinga.comCrude Oil Falls Sharply; RVL Pharmaceuticals Shares PlummetAugust 16, 2023 | msn.comRVLP: Second Quarter ResultsAugust 16, 2023 | marketwatch.comRVL Pharmaceuticals Shares Hit New Lows After Stock Sale >RVLPSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 16, 2023 | msn.comRVL Pharmaceuticals shares fall after pricing $5M stock offeringAugust 16, 2023 | finance.yahoo.comDowngrade: Here's How Analysts See RVL Pharmaceuticals plc (NASDAQ:RVLP) Performing In The Near TermAugust 16, 2023 | finance.yahoo.comRVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesAugust 15, 2023 | finance.yahoo.comQ2 2023 RVL Pharmaceuticals PLC Earnings CallAugust 14, 2023 | msn.comRVLP: Revenue Dip Prompts Spending ReversalAugust 14, 2023 | finance.yahoo.comRVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business ReviewJuly 20, 2023 | finance.yahoo.comInsiders Re-Evaluate Their US$1.6m Stock Purchase As RVL Pharmaceuticals Falls To US$43mJuly 5, 2023 | msn.comRVL Pharma (NASDAQ:RVLP) Rises on Mulling A Strategic TransactionJuly 5, 2023 | benzinga.comRVL Pharmaceuticals shares are trading higher after the company said it has been considering certain strategic alternatives.June 15, 2023 | finance.yahoo.comRVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General MeetingJune 2, 2023 | finance.yahoo.comShareholders in RVL Pharmaceuticals (NASDAQ:RVLP) are in the red if they invested three years agoMay 13, 2023 | finance.yahoo.comTime To Worry? Analysts Just Downgraded Their RVL Pharmaceuticals plc (NASDAQ:RVLP) OutlookMay 12, 2023 | finance.yahoo.comRVLP: First Quarter ResultsMay 12, 2023 | msn.comRVL Pharmaceuticals: Q1 Earnings InsightsMay 12, 2023 | finance.yahoo.comQ1 2023 RVL Pharmaceuticals PLC Earnings CallMay 10, 2023 | msn.comEarnings Preview: RVL PharmaceuticalsMay 1, 2023 | finance.yahoo.comRVLP: Selected for NewBeauty AwardMay 1, 2023 | markets.businessinsider.comBarclays Sticks to Their Buy Rating for RVL Pharmaceuticals (RVLP)See More Headlines Receive RVLP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RVLP Company Calendar Last Earnings8/14/2023Today9/27/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RVLP CUSIPN/A CIK1739426 Webwww.osmotica.com Phone(908) 809-1300FaxN/AEmployees125Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.50 High Stock Price Forecast$3.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+2,841.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,690,000.00 Net Margins-184.91% Pretax Margin-185.66% Return on Equity-130.22% Return on Assets-47.70% Debt Debt-to-Equity RatioN/A Current Ratio0.38 Quick Ratio0.36 Sales & Book Value Annual Sales$36.92 million Price / Sales0.26 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book0.17Miscellaneous Outstanding Shares111,406,000Free Float106,504,000Market Cap$9.47 million OptionableOptionable Beta1.15 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Brian A. Markison (Age 64)Chairman, Pres, CEO & Principal Financial Officer Comp: $525kMr. James D. Schaub (Age 41)Exec. VP & COO Comp: $367.2kMr. Christopher A. Klein (Age 58)Gen. Counsel & Sec. Comp: $367.2kMr. Michael J. DePetris (Age 46)Principal Accounting Officer Mr. Jarret MillerExec. VP of HRKey CompetitorsAcelRx PharmaceuticalsNASDAQ:ACRXShuttle PharmaceuticalsNASDAQ:SHPHLipella PharmaceuticalsNASDAQ:LIPOApexigenNASDAQ:APGNGuardion Health SciencesNASDAQ:GHSIView All CompetitorsInstitutional OwnershipWorth Venture Partners LLCSold 44,175 shares on 8/15/2023Ownership: 0.280%ArrowMark Colorado Holdings LLCSold 116,998 shares on 8/14/2023Ownership: 1.516%View All Institutional Transactions RVLP Stock - Frequently Asked Questions Should I buy or sell RVL Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RVL Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RVLP shares. View RVLP analyst ratings or view top-rated stocks. What is RVL Pharmaceuticals' stock price forecast for 2023? 3 equities research analysts have issued twelve-month price objectives for RVL Pharmaceuticals' stock. Their RVLP share price forecasts range from $2.00 to $3.00. On average, they expect the company's stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 2,841.2% from the stock's current price. View analysts price targets for RVLP or view top-rated stocks among Wall Street analysts. How have RVLP shares performed in 2023? RVL Pharmaceuticals' stock was trading at $1.12 at the start of the year. Since then, RVLP stock has decreased by 92.4% and is now trading at $0.0850. View the best growth stocks for 2023 here. When is RVL Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our RVLP earnings forecast. How were RVL Pharmaceuticals' earnings last quarter? RVL Pharmaceuticals plc (NASDAQ:RVLP) announced its quarterly earnings data on Monday, August, 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.13). The firm earned $8.26 million during the quarter, compared to analyst estimates of $10.38 million. RVL Pharmaceuticals had a negative trailing twelve-month return on equity of 130.22% and a negative net margin of 184.91%. What is RVL Pharmaceuticals' stock symbol? RVL Pharmaceuticals trades on the NASDAQ under the ticker symbol "RVLP." Who are RVL Pharmaceuticals' major shareholders? RVL Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include ArrowMark Colorado Holdings LLC (1.52%), Worth Venture Partners LLC (0.28%) and Citadel Advisors LLC (0.00%). How do I buy shares of RVL Pharmaceuticals? Shares of RVLP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is RVL Pharmaceuticals' stock price today? One share of RVLP stock can currently be purchased for approximately $0.09. How much money does RVL Pharmaceuticals make? RVL Pharmaceuticals (NASDAQ:RVLP) has a market capitalization of $9.47 million and generates $36.92 million in revenue each year. The company earns $-51,690,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. How many employees does RVL Pharmaceuticals have? The company employs 125 workers across the globe. How can I contact RVL Pharmaceuticals? RVL Pharmaceuticals' mailing address is 400 Crossing Blvd, Bridgewater, New Jersey 08807-2863. The official website for the company is www.osmotica.com. The company can be reached via phone at (908) 809-1300 or via email at lwilson@insitecony.com. This page (NASDAQ:RVLP) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RVL Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.